Evidence map›Paper›PMID 39419868›Full record

ArticleWorld journal of urology2024

Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study.

Zhenglin Yi, Huihuang Li, Mingyong Li, Jiao Hu, Zhiyong Cai, Zhi Liu, Chunyu Zhang, Chunliang Cheng, Yunbo He, Jinbo Chen and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhenglin Yi *Department of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Huihuang Li *Department of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Mingyong LiThe First Affiliated Hospital, Urology department, Hengyang Medical School, University of South China, Hengyang, China.
Jiao HuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Zhiyong CaiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Zhi LiuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Chunyu ZhangDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Chunliang ChengDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yunbo HeDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Jinbo ChenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xiongbing ZuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China. zuxbxyyy@126.com.ORCID http://orcid.org/0000-0002-6534-1493
Ruizhe WangDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China. ruizhe07@qq.com.

Funding

Fundamental Research Funds for Central Universities of the Central South University Fundamental Research Funds for Central Universities of the Central South UniversityHuxiang Youth Talent Support Program 2021RC3027National Natural Science Foundation of China 81873626, 81902592, 82070785Natural Science Foundation of Hunan Province 2020JJ5884, 2020JJ5916, 2024JJ6676
6 · The paper itself

Abstract

purposeDetermining the potential benefit of neoadjuvant androgen deprivation therapy (ADT) and adjuvant ADT in patients with locally advanced prostate cancer (LAPC) undergoing complete resection.

methods139 patients diagnosed with cT3-4, or cN+ LAPC in Xiangya Hospital and The First Affiliated Hospital of University of South China from 2010 to 2021 were collected. Cancer-specific survival (CSS) and overall survival (OS) of patients were assessed using Kaplan-Meier and Cox proportional risk analysis. We also analyzed the functional outcomes of two subgroups of patients who underwent radical prostatectomy (RP).

resultsOf the 182 patients with cT3-4, or cN+ LAPC, 139 patients (76.4%) were enrolled in the study with a 5-year survival rate of 82.3%. 45 patients (32.4%) received ADT alone, 46 patients (33.1%) received neoadjuvant ADT before surgery, and the remaining 48 patients (34.5%) received surgery with adjuvant ADT. Neoadjuvant ADT before surgery and surgery with adjuvant ADT were associated with significantly improved survival compared with ADT alone. Multivariate Cox models showed that neoadjuvant ADT before surgery (hazard ratio [HR], 0.29; 95% CI 0.13-0.92) or surgery with adjuvant ADT (HR, 0.26; 95% CI 0.16-0.78) was associated with improved CSS compared with ADT alone. Regional lymph node metastasis, positive lymphovascular invasion, and Gleason score 9 + were independent predictors of LAPC CSS and OS. More patients in the neoadjuvant ADT before surgery group achieved final continence status within 12 months after surgery (93.48% v 77.08%).

conclusionCSS and OS were significantly prolonged in cT3-4, or cN+ LAPC patients who received neoadjuvant ADT before surgery and surgery with adjuvant ADT compared to ADT alone.

Indexed as

Androgen AntagonistsNeoadjuvant TherapyProstatic NeoplasmsAgedChemotherapy, AdjuvantHumansMaleMiddle AgedNeoplasm StagingProstatectomyRetrospective StudiesSurvival RateAndrogen AntagonistsAndrogen deprivation therapyCancer-specific survivalLocally advanced prostate cancerOverall survivalRadical prostatectomy

Identifiers

PMID39419868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.